EL, C., LB, K., CC, v. d. P., EJT, L., TJA, v. N., A, J., . . . JM, S. (2026). Impact of less invasive axillary staging procedures after neoadjuvant systemic therapy on adjuvant systemic therapy indications in HER2-positive and triple-negative breast cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 52(6), 111785. https://doi.org/10.1016/j.ejso.2026.111785
Chicago Style (17th ed.) CitationEL, Claassens, et al. "Impact of Less Invasive Axillary Staging Procedures After Neoadjuvant Systemic Therapy on Adjuvant Systemic Therapy Indications in HER2-positive and Triple-negative Breast Cancer." European Journal of Surgical Oncology : The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 52, no. 6 (2026): 111785. https://doi.org/10.1016/j.ejso.2026.111785.
MLA (9th ed.) CitationEL, Claassens, et al. "Impact of Less Invasive Axillary Staging Procedures After Neoadjuvant Systemic Therapy on Adjuvant Systemic Therapy Indications in HER2-positive and Triple-negative Breast Cancer." European Journal of Surgical Oncology : The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 52, no. 6, 2026, p. 111785, https://doi.org/10.1016/j.ejso.2026.111785.
